Literature DB >> 26833633

Aversion learning can reduce meal size without taste avoidance in rats.

Andrea L Tracy1, Jennifer D Schurdak2, James B Chambers2, Stephen C Benoit2.   

Abstract

OBJECTIVE: Nausea and aversive food responses are commonly reported following bariatric surgery, along with post-surgical reduction in meal size. This study investigates whether a meal size limit can be conditioned by associating large meals with aversive outcomes.
METHODS: In rats, the intake of meals exceeding a pre-defined size threshold was paired with lithium chloride-induced gastric illness, and the effects on self-determined food intakes and body weight were measured.
RESULTS: Rats given LiCl contingent on the intake of a large meal learned to reliably reduce intake below this meal size threshold, while post-meal saline or LiCl before meals did not change meal size. It was further demonstrated that this is not a conditioned taste aversion and that this effect transferred to foods not explicitly trained. Finally, when rats received LiCl following all large meals, the number of small meals increased, but total food intake and body weight decreased.
CONCLUSIONS: While further work is needed, this is the first demonstration that meal size may be conditioned, using an aversion procedure, to remain under a target threshold and that this effect is distinct from taste avoidance. Corresponding reduction in food intake and body weight suggests that this phenomenon may have implications for developing weight loss strategies and understanding the efficacy of bariatric surgery.
© 2016 The Obesity Society.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26833633     DOI: 10.1002/oby.21379

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  1 in total

Review 1.  Recent advances in the modification of taste and food preferences following bariatric surgery.

Authors:  Stefany D Primeaux; Taniya de Silva; Tony H Tzeng; Monica C Chiang; Daniel S Hsia
Journal:  Rev Endocr Metab Disord       Date:  2016-06       Impact factor: 6.514

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.